TTM
13.5%
YoY change
+20.82pp
Trough year (2018)
-1016.6%
Peak year (2025)
8.4%
Latest annual
8.4%
Net Profit Margin history chart for Alnylam Pharmaceuticals (ALNY) from 2004 to 2025
Latest: 8.4%
Net Profit Margin change chart for Alnylam Pharmaceuticals (ALNY) from 2004 to 2025
Latest: +20.82pp
Net Profit Margin history table for Alnylam Pharmaceuticals (ALNY) from 2004 to 2025
| 2025 | 8.4% | +20.82pp | ||
| 2024 | -12.4% | +11.71pp | ||
| 2023 | -24.1% | +84.96pp | ||
| 2022 | -109.0% | -8.02pp | ||
| 2021 | -101.0% | +73.13pp | ||
| 2020 | -174.1% | +229.09pp | ||
| 2019 | -403.2% | +613.34pp | ||
| 2018 | -1016.6% | -470.63pp | ||
| 2017 | -545.9% | +323.68pp | ||
| 2016 | -869.6% | -163.80pp | ||
| 2015 | -705.8% | +6.97pp | ||
| 2014 | -712.8% | -523.62pp | ||
| 2013 | -189.2% | -30.29pp | ||
| 2012 | -158.9% | -89.22pp | ||
| 2011 | -69.7% | -26.16pp | ||
| 2010 | -43.5% | +3.84pp | ||
| 2009 | -47.3% | -20.04pp | ||
| 2008 | -27.3% | +140.62pp | ||
| 2007 | -167.9% | -39.41pp | ||
| 2006 | -128.5% | +622.26pp | ||
| 2005 | -750.8% | +12.53pp | ||
| 2004 | -763.3% | — |
- 20258.4%+20.82pp
- 2024-12.4%+11.71pp
- 2023-24.1%+84.96pp
- 2022-109.0%-8.02pp
- 2021-101.0%+73.13pp
- 2020-174.1%+229.09pp
- 2019-403.2%+613.34pp
- 2018-1016.6%-470.63pp
- 2017-545.9%+323.68pp
- 2016-869.6%-163.80pp
- 2015-705.8%+6.97pp
- 2014-712.8%-523.62pp
- 2013-189.2%-30.29pp
- 2012-158.9%-89.22pp
- 2011-69.7%-26.16pp
- 2010-43.5%+3.84pp
- 2009-47.3%-20.04pp
- 2008-27.3%+140.62pp
- 2007-167.9%-39.41pp
- 2006-128.5%+622.26pp
- 2005-750.8%+12.53pp
- 2004-763.3%—
Net Profit Margin values are taken from Alnylam Pharmaceuticals's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Net Profit Margin at Alnylam Pharmaceuticals (ALNY)
According to Alnylam Pharmaceuticals's latest reported financial statements, the company's latest reported net margin is 13.5%. Net profit margin is net income divided by revenue — the bottom-line share of each sales dollar that remains after all costs, including operating expenses, interest, and taxes. It is the most comprehensive profitability ratio, though it can swing on one-off items, so read it alongside the multi-year trend below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
2025's annual net margin for Alnylam Pharmaceuticals (ALNY) came in at 8.45% – expanded 20.8 percentage points year-over-year.
The highest annual net margin of 8.45% was reported in 2025. The lowest in the available history was -1016.58% in 2018.
Alnylam Pharmaceuticals Net Profit Margin by Year
Alnylam Pharmaceuticals Net Profit Margin 2025: 8.4%
In 2025, Alnylam Pharmaceuticals reported net margin of 8.45%, expanded 20.8 percentage points from 2024. This figure represents the highest annual value in the available history.
Alnylam Pharmaceuticals Net Profit Margin 2024: -12.4%
Alnylam Pharmaceuticals net margin in 2024 was -12.37%, expanded 11.7 percentage points from 2023.
Alnylam Pharmaceuticals Net Profit Margin 2023: -24.1%
2023's net margin for Alnylam Pharmaceuticals came in at -24.08%, expanded 85.0 percentage points from 2022.
Alnylam Pharmaceuticals Net Profit Margin 2022: -109.0%
Alnylam Pharmaceuticals posted net margin of -109.04% in 2022, contracted 8.0 percentage points from 2021.
Alnylam Pharmaceuticals Net Profit Margin 2021: -101.0%
Alnylam Pharmaceuticals net margin in 2021 was -101.01%.
See more financial history for Alnylam Pharmaceuticals (ALNY).
Sector peers by Net Profit Margin
Healthcare peers of Alnylam Pharmaceuticals (ALNY), ranked by their latest net margin
| 37.2% | |
| 35.0% | |
| 21.4% | |
| 20.9% | |
| 17.2% | |
| 13.6% | |
| 5.8% | |
| 2.7% |
- 37.2%
- 35.0%
- 20.9%
- 17.2%
- 13.6%
- 5.8%
Frequently asked questions
Alnylam Pharmaceuticals (ALNY) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation